Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NR3C2 genotype is associated with response to spironolactone in diastolic heart failure patients from the Aldo-DHF trial.

Pharmacotherapy - 1 Dec 2021

Dumeny Leanne, Vardeny Orly, Edelmann Frank, Pieske Burkert, Duarte Julio D, Cavallari Larisa H

Abstract excerpt

STUDY OBJECTIVE: This study aimed to determine if variants in NR3C2, which codes the target protein of spironolactone, or CYP11B2, which is involved in aldosterone synthesis, were associated with spironolactone response, focused on the primary end point of diastolic function (E/e'), in Aldosterone Receptor Blockade in Diastolic Heart Failure (Aldo-DHF) participants. DESIGN: Post-hoc genetic analysis. DATA SOURCE:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genotype
Share to Receptors, Mineralocorticoid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 34569641
DOI: 10.1002/phar.2626
PMCID: PMC8688239

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NR3C2 genotype is associated with response to spironolactone in diastolic heart failure patients from the Aldo-DHF trial.PMID 34569641Read ↗

The future of pharmacogenetics in the treatment of heart failure.Semantic proximity Read ↗

Effect of specific ADRB1/ADRB2/AGT genotype combinations on the association between survival and carvedilol treatment in chronic heart failure: a substudy of the ECHOS trial.Semantic proximity Read ↗

Beta2-adrenergic receptor genotype and pulmonary function in patients with heart failure.Semantic proximity Read ↗

Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients.Semantic proximity Read ↗

The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failureSemantic proximity Read ↗

Genetics and pharmacogenetics in heart failure.Semantic proximity Read ↗

Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function.Semantic proximity Read ↗

Pharmacogenomic study of heart failure and candesartan response from the CHARM programmeSemantic proximity Read ↗

Renin-angiotensin-aldosterone system (RAAS) pharmacogenomics: implications in heart failure management.Semantic proximity Read ↗

Effect of NR3C2 genetic polymorphisms on the blood pressure response to enalapril treatment.Semantic proximity Read ↗

Pharmacogenomics of the Natriuretic Peptide System in Heart Failure.Semantic proximity Read ↗

Genetic variants of the renin-angiotensin-aldosterone system and reverse remodeling after cardiac resynchronization therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.